Market Overview

RBC Looks For Post-Approval Data On MannKind

Share:
Related MNKD
38 Biggest Movers From Yesterday
Applied Optoelectronics, Helios And Matheson Among The Top Stocks With Short Sellers

Shares of MannKind (NASDAQ: MNKD) have traded up as much as 11 percent Monday, following Friday's announcement by the company that AFREZZA has received FDA approval.

In response to the announcement, RBC Capital released a note stating that the next key catalysts the firm sees are post-approval data and a partnership, which the firm views as "likely."

Shares of Mannking are currently trading at $11.01, up 10.1 percent.

Posted-In: RBC CapitalAnalyst Color News FDA

 

Related Articles (MNKD)

View Comments and Join the Discussion!
Loading...

Partner Center

Loading...